STOCK TITAN

Syndax Pharmaceuticals Inc - SNDX STOCK NEWS

Welcome to our dedicated news page for Syndax Pharmaceuticals (Ticker: SNDX), a resource for investors and traders seeking the latest updates and insights on Syndax Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Syndax Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Syndax Pharmaceuticals's position in the market.

Rhea-AI Summary
Incyte (Nasdaq:INCY) and Syndax Pharmaceuticals (Nasdaq:SNDX) announced the successful results from the Phase 2 AGAVE-201 trial of axatilimab for chronic GVHD. The trial met its primary endpoint, with 74% of patients at the 0.3 mg/kg dose achieving a complete or partial response within the first six months of treatment. The data were featured in the Plenary Scientific Session at the 65th American Society of Hematology Annual Meeting 2023. Incyte and Syndax expect to file a Biologics License Application (BLA) for axatilimab by year-end 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.75%
Tags
none
-
Rhea-AI Summary
Syndax Pharmaceuticals (Nasdaq: SNDX) will host an in-person investor event and live webcast on December 11, 2023, during the 65th American Society of Hematology Annual Meeting. The event will feature new data for the axatilimab and revumenib programs, and key opinion leaders from renowned institutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
conferences
-
Rhea-AI Summary
Syndax Pharmaceuticals (Nasdaq: SNDX) grants inducement awards to new employees, offering up to 158,000 shares of common stock under the 2023 Inducement Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Syndax Pharmaceuticals (SNDX) announced that data from the pivotal trial of revumenib, their oral menin inhibitor, will be featured in a late-breaking presentation at the American Society of Hematology Annual Meeting. The results continue to underscore revumenib's potential as a first- and best-in-class treatment option for patients with KMT2Ar and mNPM1 acute leukemias. The presentation will take place on December 12, 2023, and will feature topline efficacy and safety results from the pivotal AUGMENT-101 Phase 2 Study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
none
-
Rhea-AI Summary
Syndax Pharmaceuticals (Nasdaq: SNDX) CEO Michael A. Metzger will participate in a fireside chat at the Stifel Healthcare Conference on November 14, 2023, at 4:45 p.m. ET. The event will be live webcasted and accessible from the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
none
-
Rhea-AI Summary
Syndax Pharmaceuticals has granted inducement awards to ten new employees, allowing them to purchase up to 169,600 shares of common stock. The stock options will vest over four years, with 25% vesting after one year and the rest vesting monthly over 36 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Syndax Pharmaceuticals reports positive data from Phase 1 trial of revumenib, demonstrating a 36% CR/CRh rate in patients with mNPM1 AML. Registrational filings for revumenib and axatilimab on track for completion in 2023. Revumenib pivotal monotherapy results and combination data to be presented at ASH Annual Meeting. Syndax expects to launch two blockbuster therapies in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
earnings
-
Rhea-AI Summary
Syndax Pharmaceuticals will present updated data from multiple trials of revumenib, its oral menin inhibitor, at the 65th American Society of Hematology Annual Meeting. The Phase 2 portion of the AUGMENT-101 trial met its primary endpoint with a CR/CRh rate of 23% in KMT2Ar AML and ALL cohorts. Syndax plans to submit an NDA for revumenib for the treatment of R/R KMT2Ar acute leukemia by year-end. The Phase 1/2 SAVE study showed a 100% overall response rate in R/R AML patients treated with revumenib, venetoclax, and decitabine/cedazuridine. Revumenib maintenance therapy post-HSCT demonstrated durable MRD negative responses in patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.18%
Tags
none
-
Rhea-AI Summary
Syndax Pharmaceuticals announced that results from the AGAVE-201 trial of axatilimab in patients with chronic graft-versus-host disease (cGVHD) will be presented at the ASH Annual Meeting. The trial met the primary endpoint, with all three dose cohorts showing positive results. The overall response rate at the 0.3 mg/kg dose was 74%, and 60% of patients were still responding at one year. Syndax and Incyte plan to submit a BLA filing by year-end 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.18%
Tags
none
Rhea-AI Summary
Syndax Pharmaceuticals will report its Q3 2023 financial results and provide a business update on November 2. A conference call and webcast will be held to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.65%
Tags
earnings
Syndax Pharmaceuticals Inc

Nasdaq:SNDX

SNDX Rankings

SNDX Stock Data

1.96B
84.73M
0.73%
106.65%
10.7%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Waltham

About SNDX

syndax pharmaceuticals is a biotechnology company located at 35 gatehouse dr., building d, floor 3, waltham, ma 02451.